On October 10, 2023, Researcher Yang Xing from Peking University was invited to conduct academic exchanges at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and delivered an academic report titled "Research and Development and Clinical Transformation of Diagnostic and Therapeutic Probes for Prostate Cancer". Prostate cancer is a common male malignant tumor. However, traditional imaging methods have the problem of low diagnostic efficiency in detecting prostate cancer lesions. To solve this difficult problem, Researcher Yang Xing and his team introduced molecular imaging technology. By developing imaging probes with excellent performance, they effectively traced the lesions of prostate cancer, providing important information for clinical treatment decisions. The research focus of Researcher Yang Xing's team mainly lies in two aspects: Firstly, the research on diagnostic and therapeutic probes for prostate cancer. They have conducted in-depth research on the prostate-specific membrane antigen (PSMA). Using the methods of screening drug internalization and metabolic performance, they have successfully developed radionuclide and radionuclide-fluorescence dual-modal imaging probes. Such probes can be used for preoperative diagnosis and intraoperative navigation of prostate cancer, providing precise guidance for surgeries. Secondly, the expanded research on companion diagnostics. Aiming at the target Nectin-4 for ADC treatment and the immune-related target GzmB, the research team designed and screened out high-performance radionuclide imaging probes. These probes can be used for patient screening and prediction of treatment efficacy, providing more accurate guidance for clinical treatment.

Researcher Yang Xing communicated with the teachers and students of Shenzhen Institutes of Advanced Technology

Personal Profiles:

Yang Xing is a researcher and doctoral supervisor. He serves as the Deputy Director of the Scientific Research Department and the Director of the Experimental Center of Peking University First Hospital, as well as the Deputy Director of the Department of Nuclear Medicine. He is also recognized as a young overseas high-level talent by the Organization Department of the Central Committee.

Focusing on urinary system tumors, he is engaged in research in the field of molecular imaging pharmaceutical chemistry and clinical transformation. He has published more than 70 SCI academic papers as the first author or corresponding author. He has realized 4 clinical transformation research projects of brand-new radiopharmaceuticals and completed the transfer of one invention patent technology with a signing value of 20 million yuan.